碧桂园第三次延长境外债务重组支持协议同意费期限，希望年内完成境外债务重组 金十数据6月6日讯，碧桂园（02007.HK）发布公告，根据境外债务重组支持协议，继续延长重组支持 协议同意费用限期，这是碧桂园第三次延长同意费用期限。公告称，公司可酌情单方面延长早鸟重组支 持协议同意费用限期和一般重组支持协议同意费用限期。有众多债权人尚未加入重组支持协议，但彼等 支持建议重组。该等债权人正在办理其常规内部审批程序，办理后方可正式加入重组支持协议。碧桂园 的境外债务重组涉及债务的本金额为140.74亿美元。今年以来，碧桂园有意加快重组的进展，并希望能 在2025年12月31日前完成。 （澎湃） ...

港股药品股短线拉升，石药集团(01093.HK)涨超11%，泰凌医药(01011.HK)涨超4%，石四药集团 (02005.HK)涨超3%，翰森制药(03692.HK)涨超2%。 ...

港股创新药概念股午后拉升，石药集团涨超10%，绿叶制药、信达生物、中国生物制药、诺诚健华纷纷 拉升。 无需港股通，A股账户就能T+0买港股>> ...

金十数据6月6日讯，"中国海油"微信公众号消息，6月6日，中国海洋石油集团有限公司召开中层以上管 理人员大会。中央组织部有关负责同志宣布了中央关于中国海洋石油集团有限公司董事长、党组书记任 职的决定：张传江同志任中国海洋石油集团有限公司董事长、党组书记，免去其中国大唐集团有限公司 董事、总经理、党组副书记职务。相关职务任免按有关法律和章程的规定办理。 张传江任中国海洋石油集团有限公司董事长、党组书记 ...

Group 1 - The core viewpoint of the report maintains the Non-IFRS net profit forecasts for 2025 and 2026 for the company, with a current price corresponding to 20.1x and 17.5x Non-IFRS P/E for those years, respectively [1] - The company has a target price of HKD 36, which corresponds to 25x and 21x Non-IFRS P/E for 2025 and 2026, indicating a potential upside of 21.4% [1] - Recent market interest in the IP economy has led the company to enhance its IP industry chain by acquiring a 26.67% stake in Yihua Kaitian [1] Group 2 - The company's IP derivative business is expected to accelerate, with a projected GMV of over RMB 500 million in 2024, including over RMB 200 million from card products [2] - The company has opened 8 offline stores in major cities and is expanding its sales network through distribution channels [2] - The company plans to focus on lightweight peripheral products and aims to enhance both GMV and profitability through its rich IP resources and a youthful team [2] Group 3 - The company has a rich reserve of projects from Xinli Media, including several series and films planned for 2025 and 2026 [3] - The expected profit for Xinli Media in 2025 is projected to be RMB 380 million, with online business expected to remain relatively stable [3] Group 4 - The company announced the acquisition of a 26.67% stake in Yihua Kaitian for a total consideration of RMB 325 million, increasing its ownership to 31.48% [4] - Yihua Kaitian specializes in animation and game development, with projected pre-tax losses of RMB 61 million and RMB 224 million for 2023 and 2024, respectively [4] - The acquisition is expected to enhance the company's capabilities across the entire IP value chain, from incubation to commercialization [4]

Core Insights - The 11th A-TECH Conference, hosted by Times Angel, focused on early orthodontic treatment solutions, efficient management of complex cases, and the integration of digital and AI technologies in orthodontics [1][3][15] - The conference showcased Times Angel's latest advancements in medical thinking, product development, and technology implementation, emphasizing the importance of innovation in the orthodontic field [1][15] Group 1: Innovations and Product Launches - Times Angel launched the A10 expansion solution, addressing the common issue of maxillary transverse deficiency in children, with over 30% of Chinese children affected [6][10] - The company introduced the AngelMind invisible orthodontic system, which integrates biological principles and treatment methodologies, reflecting a deep understanding of medical essence [5][6] - The new "Angel Activator HG" headgear combines traditional principles with invisible treatment systems, enhancing treatment efficiency and patient compliance for Class II high-angle cases [6][10] Group 2: Advanced Technologies - Times Angel unveiled the "Angel Locking Guide" and "Angel Curved Guide" to tackle complex orthodontic challenges, improving treatment efficiency and patient comfort [7][9] - The iOrtho2025 platform was introduced, focusing on enhancing clinical efficiency and patient communication through AI-driven decision support [11][13] - The AngelScanner A8, a lightweight and efficient oral scanner, was launched, integrating seamlessly with the iOrtho platform to streamline operations and improve communication [14] Group 3: Expert Insights and Collaboration - Experts at the conference highlighted the transformative impact of AI on traditional orthodontic practices, emphasizing the need for continuous innovation [3][5] - The event featured case studies and discussions on complex treatment strategies, showcasing the collaborative efforts of global orthodontic professionals [10][15] - Times Angel aims to build a more efficient, precise, and intelligent digital orthodontic ecosystem in partnership with global dental professionals [5][15]

新华财经上海6月6日电（记者王淑娟）6日，友邦保险宣布其独立非执行主席及独立非执行董事谢仕荣 将退任，自2025年9月30日起生效，而杜嘉祺将"回归"接任。不久前，汇丰控股宣布杜嘉祺将于9月30日 退任汇丰集团主席及董事会。 此次杜嘉祺"回归"友邦备受市场瞩目。杜嘉祺曾于2010年至2017年间担任友邦保险集团首席执行官兼总 裁，2017年出任汇丰集团主席至今。 （文章来源：新华财经） 谢仕荣表示："杜嘉祺在担任友邦保险集团首席执行官兼总裁期间，对友邦保险的卓越贡献重大且深 远。他的经验及专长，包括曾担任集团首席执行官，以及近年来出任全球最大金融机构之一的集团主 席，将确保友邦保险能够受益于其卓越的领导。" 友邦保险集团首席执行官兼总裁李源祥表示："杜嘉祺为友邦保险作为一家全球领先的独立上市集团奠 定了基础。多年来，杜嘉祺在国际上的卓著声誉日益提升。我们期望受益于他在金融服务领域的丰富经 验，以及他对亚洲的热忱，带领董事会迈步向前。" 友邦保险是专注于亚洲的独立上市人寿保险集团，友邦保险今日的业务成就可追溯至1919年逾一个世纪 前于上海的发源地。截至2024年年末，友邦保险总资产值为3050亿美元。此外，友 ...

Core Viewpoint - The 2025 ASCO Annual Meeting will showcase significant research achievements of domestic innovative drugs, highlighting their potential in oncology treatment [1] Group 1: Innovative Drug Highlights - Several innovative drug molecules with first-in-class or best-in-class potential will present data, including IBI363 from Innovent Biologics, SKB264 from Kelun-Biotech, and others [1] - IBI363 is the world's first next-generation IO dual antibody designed with IL 2α bias, showing promising efficacy in treating IO-resistant tumors such as NSCLC, melanoma, and CRC [2] Group 2: Clinical Data and Efficacy - In a Phase I clinical study, IBI363 demonstrated an overall response rate (ORR) of 43.3% and a disease control rate (DCR) of 90.0% in squamous NSCLC patients at a 3 mg/kg dosage, with a median progression-free survival (mPFS) of 7.3 months [2] - For adenocarcinoma patients previously treated with PD-(L)1 therapy, the 3 mg/kg group showed an ORR of 76.0% and a DCR of 90.0%, with an mPFS of 4.2 months [2] Group 3: Comparative Efficacy - IBI363 exhibited significant clinical activity in IO-resistant lung squamous and adenocarcinoma patients, outperforming existing therapies such as docetaxel and various immune combination treatments [3] Group 4: Colorectal Cancer Potential - IBI363 also shows promise in late-line CRC treatment, with clinical studies indicating an overall survival (OS) of 16.1 months for patients treated with IBI363 monotherapy [5][6] - Compared to standard treatments like TAS-102 combined with bevacizumab, IBI363 demonstrated superior survival outcomes in patients with worse baseline characteristics [6]

金十数据6月6日讯，汇丰环球研究发表报告表示，将石药集团(01093.HK)评级从"持有"上调至"买入"， 目标价从4.7港元上调至9.5港元，对其估值由综合估值方式改为按现金流折现率估算，潜在升幅21%。 该行指石药今年首季度收入和净利润分别按年下降22%和8%，但产品销售和利润按季增长12%和60%， 显示出从集中采购压力下的逐步复苏。同时，该行对石药集团的创新药物更加乐观，原因如下：①石药 集团今年5月30日公告显示，公司正在推进三项潜在的许可交易，表明业务拓展进展比该行先前预期更 强更快；②SYS6010的稳健数据。 汇丰研究：升石药集团评级至"买入" 上调目标价至9.5港元 ...

康方生物否认出售临床用药 今年2月，李某美突发咳嗽，后来发展到呼吸困难，转到西南医院就诊。医院为其开具的诊断证明中第 一条显示为"免疫检查点抑制剂相关肺炎"。李某美患有宫颈癌，她表示自己仅用过名为"卡度尼利"的免 疫药物。据其介绍，2024年4月肿瘤复发的她在重庆大学附属肿瘤医院住院期间，经主治医生李某介 绍，在康方生物医药代表冉某元处购买了名为卡度尼利单抗注射液（以下简称卡度尼利单抗）的抗癌 药，价格为13220元/支，医药代表表示买6支就可以为其提供一年的用药。李某美支付了6支卡度尼利单 抗的费用，共计79320元。从2024年4月到今年2月共用药约70支，其中正规包装的药物用了11支，后来 用的约60支均为纯白色小包装，并印有"仅供临床研究使用"的字样。李某美表示，自己取药是在冉某元 指定的一家名为"爱心直达"的DTP药房，输液则在药房隔壁的诊所完成。 卡度尼利单抗为康方生物旗下药物，2022年6月，国家药监局通过优先审评审批程序，附条件批准卡度 尼利单抗注射液（商品名为开坦尼）上市，适用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患 者的治疗。彼时，该药为我国自主研发的创新双特异性抗体，靶向人PD- ...